人 FCRL1 抗体对
01AB02183
Fc receptor like 1 (FCRL1) is a type I transmembrane glycoprotein of the immunoglobulin receptor superfamily, preferentially expressed on the surface of mature B cells. It contains three extracellular Ig-like domains and a cytoplasmic tail featuring ITAM-like motifs that recruit signaling effectors to modulate B-cell receptor (BCR) signaling. FCRL1 acts as a BCR co-receptor, enhancing B-cell activation, proliferation, and calcium mobilization, while also regulating downstream pathways such as ERK and NF-kappaB in a context-dependent manner. Pathologically, FCRL1 is broadly expressed in various B-cell malignancies, including diffuse large B-cell lymphoma and Burkitt lymphoma, where it supports survival signaling through the AKT and NF-kappaB pathways. Its restricted expression and role in B-cell signaling make FCRL1 a significant biomarker and a potential therapeutic target for B-cell-driven leukemias and lymphomas.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- FCRL1
- 基因别名
- FCRH1; IFGP1; IRTA5
- 蛋白别名
- Fc receptor like 1; FCRL1
- UniProt
- Q96LA6
- 物种
- Human
产品详情
- 靶点名称
- FCRL1
- 蛋白名称
- Fc receptor like 1
- 蛋白别名
- Fc receptor-like protein 1; FcR-like protein 1; FcRL1; Fc receptor homolog 1; FcRH1; IFGP family protein 1; hIFGP1; Immune receptor translocation-associated protein 5; CD antigen CD307a
- 靶点基因名
- FCRL1
- 基因别名
- FCRH1; IFGP1; IRTA5
- UniProt
- Q96LA6
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Fc receptor like 1 (FCRL1) is a type I transmembrane glycoprotein of the immunoglobulin receptor superfamily, preferentially expressed on the surface of mature B cells. It contains three extracellular Ig-like domains and a cytoplasmic tail featuring ITAM-like motifs that recruit signaling effectors to modulate B-cell receptor (BCR) signaling. FCRL1 acts as a BCR co-receptor, enhancing B-cell activation, proliferation, and calcium mobilization, while also regulating downstream pathways such as ERK and NF-kappaB in a context-dependent manner. Pathologically, FCRL1 is broadly expressed in various B-cell malignancies, including diffuse large B-cell lymphoma and Burkitt lymphoma, where it supports survival signaling through the AKT and NF-kappaB pathways. Its restricted expression and role in B-cell signaling make FCRL1 a significant biomarker and a potential therapeutic target for B-cell-driven leukemias and lymphomas.